Evidence map›Paper›PMID 32015343›Full record

Trial reportBlood cancer journal2020

Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma.

Siyang Leng, Divaya Bhutani, Shahzad Raza, Amer Assal, Samuel Pan, Jianhua Hu, Alexander Wei, Markus Mapara, Suzanne Lentzsch

Abstract readClinical Trial, Phase IClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Siyang LengDivision of Hematology/Oncology, Columbia University Irving Medical Center, 161 Fort Washington Ave, New York, NY, 10032, USA. siyang.leng@gmail.com.
Divaya BhutaniDivision of Hematology/Oncology, Columbia University Irving Medical Center, 161 Fort Washington Ave, New York, NY, 10032, USA.
Shahzad RazaSaint Luke's Health System, 4321 Washington St Ste 4000, Kansas City, MO, 64111, USA.ORCID http://orcid.org/0000-0002-2739-2265
Amer AssalDivision of Hematology/Oncology, Columbia University Irving Medical Center, 161 Fort Washington Ave, New York, NY, 10032, USA.
Samuel PanDepartment of Biostatistics, Columbia University Mailman School of Public Health, 622 West 168th St, New York, NY, 10032, USA.
Jianhua HuDepartment of Biostatistics, Columbia University Mailman School of Public Health, 622 West 168th St, New York, NY, 10032, USA.
Alexander WeiDepartment of Medicine, Columbia University Irving Medical Center, 161 Fort Washington Ave, New York, NY, 10032, USA.
Markus MaparaDivision of Hematology/Oncology, Columbia University Irving Medical Center, 161 Fort Washington Ave, New York, NY, 10032, USA.
Suzanne LentzschDivision of Hematology/Oncology, Columbia University Irving Medical Center, 161 Fort Washington Ave, New York, NY, 10032, USA.

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3M
NCI NIH HHS P30 CA013696
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideDexamethasoneFemaleFollow-Up StudiesHumansMaleMiddle AgedMultiple MyelomaOligopeptidesPrognosisBendamustine HydrochloridecarfilzomibDexamethasoneOligopeptides

Identifiers

PMID32015343
PMCPMC6997347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.